| Combination of | |
|---|---|
| Finasteride | 5α-reductase inhibitor |
| Tadalafil | Phosphodiesterase 5 (PDE5) inhibitor |
| Clinical data | |
| Trade names | Entadfi |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Finasteride/tadalafil, sold under the brand name Entadfi, is a fixed-dose combination medication used for the treatment of benign prostatic hyperplasia (BPH).[1][2][3] It contains finasteride and tadalafil.[1] It is taken by mouth.[1]
It was approved for medical use in the United States in December 2021.[1][4]
Medical uses[edit]
Finasteride/tadalafil is indicated to treat benign prostatic hyperplasia (BPH) in men.[1]
References[edit]
- ^ a b c d e f "Entadfi- finasteride and tadalafil capsule". DailyMed. Retrieved 24 December 2021.
- ^ Elkelany OO, Owen RC, Kim ED (2015). "Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus". Therapeutics and Clinical Risk Management. 11: 507–13. doi:10.2147/TCRM.S80353. PMC 4386768. PMID 25848297.
- ^ Olesovsky C, Kapoor A (August 2016). "Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia". Therapeutic Advances in Urology. 8 (4): 257–271. doi:10.1177/1756287216650132. PMC 5131741. PMID 27928428.
- ^ "Veru Announces FDA Approval of Entadfi, a New Treatment for Benign Prostatic Hyperplasia". Veru (Press release). 13 December 2021. Retrieved 17 December 2021.
